Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244513 | 0.90 | FFAR1 (0.72) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL2244510 | 0.90 | FFAR1 (0.72) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL12021118 | 0.90 | FFAR1 (0.64) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL14273217 | 0.89 | FFAR1 (0.63) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL14980205 | 0.89 | FFAR1 (0.63) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL12021109 | 0.88 | FFAR1 (0.62) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL13318210 | 0.83 | FFAR1 (0.68) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL12020986 | 0.83 | FFAR1 (0.68) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL13350442 | 0.83 | FFAR1 (0.65) | FFAR1MRGPRX4PPARDPPARAPPARG | |
| SCHEMBL12021108 | 0.83 | FFAR1 (0.64) | FFAR1MRGPRX4PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | FFAR1 25/4885MRGPRX4 74/4885PPARD 36/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | FFAR1 25/4885MRGPRX4 74/4885PPARD 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.